Viemed Healthcare earnings were $12.3M for the trailing 12 months ending Mar 31, 2025, with 18.5% growth year over year. The latest VMD earnings report on Mar 31, 2025 announced Q1 2025 earnings of $2.6M, down 39.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, VMD reported annual earnings of $11.3M, with 10% growth. The next VMD earnings date is Aug 6, 2025.
VMD past earnings growth
How has VMD's earnings growth performed historically?
What were Viemed Healthcare's earnings last quarter?
On VMD's earnings call on Invalid Date, Viemed Healthcare (NASDAQ: VMD) reported Q1 2025 earnings per share (EPS) of $0.07, up 75% year over year. Total VMD earnings for the quarter were $2.63 million. In the same quarter last year, Viemed Healthcare's earnings per share (EPS) was $0.04.
The next VMD earnings call is Invalid Date. Add VMD to your watchlist to be reminded of Viemed Healthcare's next earnings date.
Is Viemed Healthcare profitable or losing money?
As of the last Viemed Healthcare earnings report, Viemed Healthcare is currently profitable. Viemed Healthcare's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $12.29 million, a 18.96% increase year over year.
What was VMD's earnings growth in the past year?
As of Viemed Healthcare's earnings date in Invalid Date, Viemed Healthcare's earnings has grown 18.52% year over year. This is 32.27 percentage points lower than the US Medical Devices industry earnings growth rate of 50.78%. VMD earnings in the past year totalled $12.29 million.
What are Viemed Healthcare's earnings expectations?
The current EPS estimate for Viemed Healthcare's earnings report in Invalid Date is $0.09.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.